Ticker Details
Cue Biopharma, Inc. Cue Biopharma Inc is a biopharmaceutical company developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders.
IPO Date:	January 2, 2018
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$27.27M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.26 | 3.82%
Avg Daily Range (30 D):	$0.02 | 6.85%
Avg Daily Range (90 D):	$0.03 | 4.82%

Institutional Daily Volume
Avg Daily Volume:	.24M
Avg Daily Volume (30 D):	1.33M
Avg Daily Volume (90 D):	.59M

Trade Size
Avg Trade Size (Sh.):	131
Avg Trade Size (Sh.) (30 D):	478
Avg Trade Size (Sh.) (90 D):	440

Institutional Trades
Total Institutional Trades:	183
Avg Institutional Trade:	$2.16M
Avg Institutional Trade (30 D):	$.62M
Avg Institutional Trade (90 D):	$.62M
Avg Institutional Trade Volume:	.22M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.18M
Avg Closing Trade (30 D):	$.62M
Avg Closing Trade (90 D):	$.62M
Avg Closing Volume:	243.1K

News

Jul 23, 2025 @ 1:26 PM High‑Growth Oncology Market Projected For U... Source: Prnewswire

Jun 24, 2025 @ 8:48 PM Cue Biopharma Receives FDA Feedback on Pre-IND Bri... Source: N/A

Apr 15, 2025 @ 2:23 AM Cue Biopharma Announces Pricing of Approximately $... Source: Globe Newswire

Apr 15, 2025 @ 2:23 AM Cue Biopharma Announces Pricing of Approximately $... Source: N/A

Apr 14, 2025 @ 9:00 PM Boehringer Ingelheim and Cue Biopharma partner to ... Source: N/A

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-.41	$-.07	$-.09
Diluted EPS	$-.41	$-.07	$-.09
Revenue	$7.1M	$2.15M	$2.95M
Gross Profit
Net Income / Loss	$-37.68M	$-7.45M	$-8.48M
Operating Income / Loss	$-38.16M	$-7.6M	$-8.64M
Cost of Revenue
Net Cash Flow	$-20.72M	$-15.79M	$14.36M
PE Ratio